Healthcare, Pharma & Life Sciences

Wholistic Matters Cuts CE Costs to $29-$79 Per Course for Practitioners

Image
Wholistic Matters Cuts CE Costs to $29-$79 Per Course for Practitioners

Palmyra, Wis. – – October 05, 2026 -- Wholistic Matters, powered by Standard Process, has launched an expanded continuing education catalog pricing courses between $29 and $79, undercutting an industry standard of $30 to $50 per credit hour.

Pricing structure targets rising CE costs for practitioners

The self-paced, on-demand courses are tiered at $29 for 1-credit offerings, $59 for 3-credit courses, $69 for 4-credit courses, and $79 for 5-credit courses. The courses carry accreditation across multiple practitioner boards, including ND, DC, LAc, CNS, ACBN, BCHN, NTP, and California RN.

Talkiatry Earns Joint Commission Gold Seal for Behavioral Health

Image
Talkiatry Earns Joint Commission Gold Seal for Behavioral Health

New York – October 05, 2026 -- Talkiatry, the largest psychiatric provider group in the U.S., has received The Joint Commission's Gold Seal of Approval® for Behavioral Health, covering care delivered to more than 170 million lives nationwide.

Accreditation follows four million patient visits and rapid national expansion

The accreditation arrives shortly after Talkiatry surpassed four million patient visits and serves as the preferred in-network psychiatry partner for more than 70 U.S. health systems. To earn the designation, the company underwent a comprehensive review of its operations, patient care delivery, and privacy and security practices, followed by on-site surveyor observations and interviews.

Global Coalition Launches 30x30x50 Challenge to Cut Stroke, Expand Screening

New York – October 05, 2026 -- A new multisector coalition launched the 30x30x50 Brain Challenge, pledging to cut stroke incidence by 30 percent and increase primary-care cognitive screening by 50 percent across 30 global cities by 2031.

Atria-coordinated coalition unites pharma, tech and the UN behind brain health delivery

The International Brain Health Coalition (IBC), coordinated by the Atria Research and Global Health Institute (ARGHI), brings together patients, multilateral institutions including the United Nations, and organizations spanning medicine, technology, and finance. Collaborators include Eli Lilly and Company, Bristol Myers Squibb, Microsoft, the Royal Bank of Canada, the American Heart Association, UN Women, Western University, and the AI-Mind Institute in Norway.

Resero Bio Urine Test Predicts Bladder Cancer Treatment Response

Image
Resero Bio Urine Test Predicts Bladder Cancer Treatment Response

San Carlos, Calif. – October 05, 2026 -- A non-invasive urine test can now predict whether bladder cancer patients will respond to immunotherapy before treatment even begins, according to a Stanford-led study published in Nature Medicine and announced by Resero Bio.

Study analyzed 683 urine samples to validate cell-free RNA platform

Researchers from Stanford Cancer Institute and the VA Palo Alto Health Care System used uRARE-seq, Resero Bio's proprietary targeted cfRNA sequencing method, to analyze 683 urine samples from bladder cancer patients and controls. The platform distinguished low-grade from high-grade tumors and non-muscle invasive from muscle-invasive disease, determinations that currently require tissue biopsy or surgical resection.

Insmed CFO Sara Bonstein to Depart Oct. 30; Guidance Reaffirmed

Image
Insmed CFO Sara Bonstein to Depart Oct. 30; Guidance Reaffirmed

Bridgewater, N.J. – – October 05, 2026 -- Insmed Incorporated (Nasdaq: INSM) announced that Chief Financial Officer Sara Bonstein will step down on October 30, 2026, after nearly seven years in the role, during which the company raised more than $4.2 billion in capital.

Bonstein exits after helping raise $4.2 billion for Insmed

Bonstein will remain CFO through the company's third-quarter 2026 earnings report and will participate in the earnings call on October 29, 2026, before departing the following day. Insmed has launched a search with an executive search firm to identify her successor. The company stated the transition is unrelated to any disagreement over accounting practices, financial statements, internal controls, or operations.

HanchorBio Wins FDA IND Clearance for Trispecific Drug HCB303

Image
HanchorBio Wins FDA IND Clearance for Trispecific Drug HCB303

Taipei, Shanghai and San Francisco – October 05, 2026 -- HanchorBio, Inc. (TWSE: 7827) said the U.S. Food and Drug Administration has cleared the investigational new drug application for HCB303, clearing the path for the company's second trispecific immunotherapy to enter human testing.

FDA clearance unlocks Phase 1 trial for advanced solid tumors

The clearance allows HanchorBio to launch a Phase 1 first-in-human, dose-escalation, multi-regional study (HCB303-ONC-101) in patients with advanced, relapsed or refractory solid tumors who have exhausted standard treatment options. The trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, biomarkers and preliminary antitumor activity. The decision follows pre-IND feedback HanchorBio received from the FDA in August 2026.

Energenesis Signs Korea MOU with Yoo Young Pharm for Wound Drug

Image
Energenesis Signs Korea MOU with Yoo Young Pharm for Wound Drug

Taipei – October 05, 2026 -- Energenesis Biomedical Co., Ltd. (TWSE: 6657) has signed a Memorandum of Understanding with South Korea's Yoo Young Pharm. Co., Ltd. (YYP) to pursue development, registration, and commercialization of its diabetic foot ulcer drug candidate ENERGI-F703DFU in the Korean market.

MOU sets framework for Korea rights on ENERGI-F703DFU

Under the agreement, YYP would gain rights to develop, register, and commercialize ENERGI-F703DFU in Korea, leveraging Energenesis' clinical data package, including Phase III trial results, alongside YYP's regional commercial and clinical network. The MOU establishes a framework for continued negotiations; terms of a definitive agreement remain subject to further discussion between the two companies.

KMM Group Adds Operations, Finance Leaders After RS2 Investment

Image
KMM Group Adds Operations, Finance Leaders After RS2 Investment

United States – – October 05, 2026 -- Medical device contract manufacturer KMM Group has named Amy Goff and Erica Blake to senior leadership roles, deepening its operational and financial bench as the company expands production capacity following a platform investment from RS2 Healthcare Partners.

KMM strengthens leadership after July 2026 CEO appointment and RS2 investment

The hires follow J. Mark King's July 2026 appointment as president and CEO and the completion of RS2 Healthcare Partners' platform investment in KMM. King said the additions align with KMM's expansion plans, citing Goff's operations and supply chain background and Blake's finance experience in complex manufacturing transitions.

Moberg Pharma: MOB-015 Cures Nail Fungus Despite Terbinafine Resistance

Stockholm – October 05, 2026 -- Moberg Pharma AB (OMX: MOB) reported that its topical onychomycosis treatment MOB-015 achieved mycological cure in 74.3% of evaluable Phase 3 patients regardless of baseline antifungal susceptibility, according to new peer-reviewed data published in the Journal of Fungi.

Researchers screened 506 dermatophyte isolates for terbinafine resistance markers

The analyses draw on the company's completed North American Phase 3 trial of MOB-015, a once-daily treatment applied for 48 weeks. The work was conducted with Professor Mahmoud Ghannoum at Case Western Reserve University in Cleveland, Ohio, examining in vitro terbinafine susceptibility across the full isolate population.

AnnJi Advances AJ201 into Phase 3 for Rare Kennedy's Disease

Taipei – October 05, 2026 -- AnnJi Pharmaceutical Co., Ltd. (TPEx: 7754) is proceeding with the U.S. portion of its pivotal Phase 3 ROMA-KD trial for AJ201, an oral small molecule targeting spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, a rare inherited neuromuscular disorder with no FDA-approved treatment.

AJ201 becomes the only investigational SBMA therapy in Phase 3 development worldwide

AnnJi submitted the Phase 3 protocol to the U.S. FDA under its active Investigational New Drug application and will now move to activate U.S. trial sites. The global, multicenter, randomized, double-blind, placebo-controlled ROMA-KD study is designed to evaluate efficacy and safety in ambulatory patients with symptomatic SBMA, with approximately 200 patients expected to enroll worldwide and the United States serving as a key region.